$13.68
0.96%
Nasdaq, Nov 17, 04:00 pm EST. Closed.
ISIN
IL0011316309
Symbol
MDWD

MediWound Ltd. Stock price

$13.68
+0.98 7.72% 1M
-2.72 16.59% 6M
-4.78 25.89% YTD
-4.70 25.57% 1Y
+5.35 64.23% 3Y
-8.02 36.96% 5Y
-26.40 65.86% 10Y
-107.21 88.68% 20Y
Nasdaq, Closing price Tue, Nov 17 2026
+0.13 0.96%
ISIN
IL0011316309
Symbol
MDWD
Industry

Is MediWound Ltd. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,087 stocks worldwide.

Key metrics

Basic
Market capitalization
$174.9m
Enterprise Value
$148.2m
Net debt
positive
Cash
$35.3m
Shares outstanding
12.9m
Valuation
P/E
negative
P/S | estimate
14.7 | 7.2
EV/Sales | estimate
12.5 | 6.1
EV/FCF | ex SBC
negative | negative
P/B
4.9
Financial Health
Equity Ratio
50.6%
Return on Equity
-54.7%
ROCE
-59.6%
ROIC
-177.7%
Debt/Equity
0.2
Share-Based Compensation & Dilution
SBC | % of Revenue
$2.8m | 23.6%
SBC as % of FCF
-
SBC Growth 1Y
-21.8%
Share Count Growth 1Y
18.7%
Shareholder Yield
-18.7%
Financials
Revenue | estimate
$11.9m | $24.1m
EBITDA
$-29.9m
EBIT
$-31.8m
Net Income
$-20.2m
Free Cash Flow | ex SBC
$-28.5m | $-31.3m
Growth
Revenue | estimate
-40.3% | 42.4%
EBITDA
-44.9%
EBIT
-43.6%
Net Income
27.8%
Free Cash Flow
-48.1%
Margin
Gross
15.5%
EBITDA
-251.8%
EBIT
-267.8%
Net
-170.1%
Free Cash Flow | ex SBC
-240.5% | -264.1%
More
EPS
$-1.6
FCF per Share
$-2.2
Short interest
15.7%
Employees
121
Rev per Employee
$140.0k

MediWound Ltd. Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a MediWound Ltd. forecast:

11x Buy
92%
1x Hold
8%

Analyst Opinions

12 Analysts have issued a MediWound Ltd. forecast:

Buy
92%
Hold
8%

MediWound Ltd. Events

Past Events
NOV
12
Q3 2026 Earnings Call
5 days ago
AUG
13
Q2 2026 Earnings Call
3 months ago
MAY
27
Q1 2026 Earnings Call
6 months ago
MAR
5
Q4 2025 Earnings Call
9 months ago
NOV
20
Q3 2025 Earnings Call
12 months ago

Financial data from MediWound Ltd.

Jun '26
+/-
%
12 12
40% 40%
100%
- Direct Costs 10 10
38% 38%
85%
1.83 1.83
50% 50%
15%
- Selling and Administrative Expenses 15 15
8% 8%
127%
- Research and Development Expense 19 19
60% 60%
160%
-30 -30
45% 45%
-252%
- Depreciation and Amortization 1.89 1.89
25% 25%
16%
EBIT (Operating Income) EBIT -32 -32
44% 44%
-268%
Net Profit -20 -20
28% 28%
-170%

In millions USD.

Don't miss a Thing! We will send you all news about MediWound Ltd. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

MediWound Ltd. Stock News

Neutral
GlobeNewsWire
●
one day ago
MediWound to Host Virtual KOL Event on EscharEx ® Phase III VALUE Study and Commercial Opportunity on December 2, 2026 Leading wound care experts to discuss Phase II clinical evidence, the pivotal Phase III VALUE study, and the estimated $1.05 billion U.S. annual peak sales potential YAVNE, Israel, November 16, 2026 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq: MDWD), a global leader in next-gener...
Neutral
GlobeNewsWire
●
5 days ago
EscharEx® Phase III VALUE Trial Advancing; Interim Assessment and Enrollment Completion Expected by End of First Quarter 2027
More MediWound Ltd. News

Company Profile

MediWound Ltd. is a biopharmaceutical company engaging in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. Its product is NexoBrid. The company was founded by Lior Rosenberg and Marian Gorecki in 2001 and is headquartered in Yavne, Israel.

Head office Israel
CEO Mr. Gonen
Employees 121
Founded 2000
Website www.mediwound.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today